IJF Stock Overview A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteICON Public Limited Company Competitors Price History & Performance
Summary of share price highs, lows and changes for ICON Historical stock prices Current Share Price US$196.10 52 Week High US$316.30 52 Week Low US$174.85 Beta 1.2 1 Month Change 7.72% 3 Month Change -26.72% 1 Year Change -23.10% 3 Year Change -28.43% 5 Year Change 28.17% Change since IPO 2,364.34%
Recent News & Updates
ICON plc Announces Appointment of Barry Balfe as Chief Operating Officer Dec 18 ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $250 million worth of its shares. Oct 25
Third quarter 2024 earnings released: EPS: US$2.38 (vs US$1.99 in 3Q 2023) Oct 24
ICON Public Limited Company Updates Earnings Guidance for the Full Year 2024 Oct 24
ICON Public Limited Company to Report Q3, 2024 Results on Oct 23, 2024 Sep 27 ICON plc Announces Chief Financial Officer Changes Aug 15
See more updates
ICON plc Announces Appointment of Barry Balfe as Chief Operating Officer Dec 18 ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $250 million worth of its shares. Oct 25
Third quarter 2024 earnings released: EPS: US$2.38 (vs US$1.99 in 3Q 2023) Oct 24
ICON Public Limited Company Updates Earnings Guidance for the Full Year 2024 Oct 24
ICON Public Limited Company to Report Q3, 2024 Results on Oct 23, 2024 Sep 27 ICON plc Announces Chief Financial Officer Changes Aug 15
Insufficient new directors Aug 01
Second quarter 2024 earnings released: EPS: US$1.78 (vs US$1.41 in 2Q 2023) Jul 25
ICON Public Limited Company Updates Earnings Guidance for the Full-Year 2024 Jul 25
ICON Public Limited Company Announces Board Changes Jul 24
ICON Public Limited Company to Report Q2, 2024 Results on Jul 24, 2024 Jul 02
ICON Public Limited Company, Annual General Meeting, Jul 23, 2024 Jun 13
ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2024 May 31
Now 21% undervalued Apr 30
First quarter 2024 earnings released: EPS: US$2.27 (vs US$1.43 in 1Q 2023) Apr 25 Brendan Brennan to Resign as Chief Financial Officer of ICON Public Limited Company in Fourth Quarter 2024
ICON Public Limited Company to Report Q1, 2024 Results on Apr 24, 2024 Mar 26
Full year 2023 earnings released: EPS: US$7.46 (vs US$6.20 in FY 2022) Feb 22 ICON Public Limited Company Reaffirms Earnings Guidance for the Full Year 2024
Now 21% undervalued Feb 01
ICON Public Limited Company to Report Q4, 2023 Results on Feb 21, 2024 Jan 31
ICON Public Limited Company Provides Earnings Guidance for the Full Year 2023 and 2024 Jan 10
Third quarter 2023 earnings released: EPS: US$1.99 (vs US$1.96 in 3Q 2022) Oct 26 ICON Public Limited Company (NasdaqGS:ICLR) acquired Philips Pharma Solutions.
ICON Public Limited Company to Report Q3, 2023 Results on Oct 25, 2023 Sep 22
ICON plc Releases Expanded End-To-End Clinical Trial Tokenisation Solution Sep 21
ICON plc Partners with the U.S. Biomedical Advanced Research and Development Authority to Execute Next Generation COVID-19 Vaccines Clinical Trial Sep 14
Second quarter 2023 earnings released: EPS: US$1.41 (vs US$1.42 in 2Q 2022) Jul 27
ICON Public Limited Company to Report Q2, 2023 Results on Jul 26, 2023 Jun 28
ICON Public Limited Company, Annual General Meeting, Jul 25, 2023 Jun 13
Now 21% undervalued after recent price drop May 01
First quarter 2023 earnings released: EPS: US$1.43 (vs US$1.37 in 1Q 2022) Apr 28
Now 22% undervalued Mar 11
Full year 2022 earnings released: EPS: US$6.20 (vs US$2.28 in FY 2021) Feb 24
ICON Public Limited Company to Report Q4, 2022 Results on Feb 22, 2023 Jan 27
Icon Public Limited Company Reaffirms Revenue Guidance for Full Year 2022 and Provides Revenue Guidance for Full Year 2023 Jan 11
Insufficient new directors Jan 10
Third quarter 2022 earnings released: EPS: US$1.96 (vs US$1.17 loss in 3Q 2021) Nov 03 ICON Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022 Sep 27
Second quarter 2022 earnings released: EPS: US$1.42 (vs US$1.40 in 2Q 2021) Jul 29 Icon Public Limited Company Revises Earnings Guidance for the Year 2022
ICON Public Limited Company to Report Q2, 2022 Results on Jul 27, 2022 Jun 22
ICON Public Limited Company, Annual General Meeting, Jul 26, 2022 Jun 18
First quarter 2022 earnings released: EPS: US$1.37 (vs US$1.84 in 1Q 2021) Apr 30
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24 ICON Public Limited Company (NasdaqGS:ICLR) announces an Equity Buyback for $100 million worth of its shares.
Now 21% undervalued after recent price drop Feb 12
Now 21% undervalued Jan 14
ICON Public Limited Company Reaffirms Earnings Guidance for the Year 2021 Jan 13
Third quarter 2021 earnings released: US$1.17 loss per share (vs US$1.74 profit in 3Q 2020) Nov 06
Investor sentiment improved over the past week Jul 30
ICON Public Limited Company Provides Earnings Guidance for the Year 2021 Jul 23
Second quarter 2021 earnings released: EPS US$1.40 (vs US$0.91 in 2Q 2020) Jul 22
ICON Public Limited Company (NasdaqGS:ICLR) completed the acquisition of PRA Health Sciences, Inc. (NasdaqGS:PRAH). Jul 03
First quarter 2021 earnings released: EPS US$1.84 (vs US$1.63 in 1Q 2020) May 03
ICON Public Limited Company Raises Earnings Guidance for the Full Year 2021 Apr 29
New 90-day low: €151 Feb 26
ICON Public Limited Company (NasdaqGS:ICLR) entered into an agreement to acquire PRA Health Sciences, Inc. (NasdaqGS:PRAH) for $10.8 billion. Feb 25
Full year 2020 earnings released: EPS US$6.29 (vs US$6.85 in FY 2019) Feb 25
Revenue beats expectations Feb 25
ICON Public Limited Company Announces the Release of Two New Digital Solutions Supporting Clinical Research Sites and Sponsors Feb 09
New 90-day high: €176 Jan 14
ICON Supports Pfizer and BioNTech on the Investigational COVID-19 Vaccine Trial Jan 05
Third quarter earnings released Oct 25
Third-quarter earnings released: Revenue beats expectations Oct 25
Third quarter earnings released Oct 22
Third-quarter earnings released: Revenue beats expectations Oct 22
New 90-day high: €169 Oct 02
ICON Public Limited Company (NasdaqGS:ICLR) acquired remaining stake in MeDiNova Limited. Jul 31
New 90-day high - €168 Jul 23 Shareholder Returns IJF DE Life Sciences DE Market 7D -2.2% -4.2% -2.6% 1Y -23.1% -5.3% 7.1%
See full shareholder returns
Return vs Market: IJF underperformed the German Market which returned 8% over the past year.
Price Volatility Is IJF's price volatile compared to industry and market? IJF volatility IJF Average Weekly Movement 7.1% Life Sciences Industry Average Movement 7.2% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: IJF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IJF's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
Show more ICON Public Limited Company Fundamentals Summary How do ICON's earnings and revenue compare to its market cap? IJF fundamental statistics Market cap €16.28b Earnings (TTM ) €721.72m Revenue (TTM ) €8.02b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IJF income statement (TTM ) Revenue US$8.31b Cost of Revenue US$5.85b Gross Profit US$2.46b Other Expenses US$1.71b Earnings US$747.89m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 17:39 End of Day Share Price 2024/12/19 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ICON Public Limited Company is covered by 45 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Armelle Moulin AlphaValue Gregory Bolan Avondale Partners Eric Coldwell Baird
Show 42 more analysts